Gilead Sciences and Lakefront Biotherapeutics Acquire Ouro Medicines to Expand Autoimmune Pipeline

Gilead Sciences (NASDAQ: GILD) and Lakefront Biotherapeutics have acquired Ouro Medicines, a move aimed at strengthening their inflammation and immunology pipelines. The acquisition centers on gamgertamig, a clinical-stage T cell engager for autoimmune diseases like AIHA and ITP.

By Maham Fatima Sun, June 7, 2026 at 7:39 AM GMT+3 2 min read · Yahoo Finance · June 7, 2026, 04:39 UTC

Tickers: $GILD

Topics: Autoimmune Diseases Biotechnology Mergers Pharmaceuticals

Read the full article at Yahoo Finance

More World news

Sprott Physical Gold Trust USD Reports Q3 Net Income of $508.82 Million Seeking Alpha · November 12, 2026, 18:07 UTC
NYSE Gains $500 Billion in Market Capitalization via Nine Major Listing Transfers PR Newswire · November 12, 2026, 18:05 UTC
PenFed Foundation Grants $25,000 to Northern Virginia Vietnam Veterans Foundation PR Newswire · November 12, 2026, 18:06 UTC
Allstate Announces Quarterly Dividend of $1.08 Per Share Seeking Alpha · November 12, 2026, 18:01 UTC
Pinnacle Bankshares Increases Quarterly Dividend to $0.35 Per Share Seeking Alpha · November 12, 2026, 18:02 UTC
Avidbank Reports Third Quarter 2026 Earnings Growth Driven by Core Deposits and C&I Lending Motley Fool · November 12, 2026, 18:00 UTC
Equinor Raises Production Guidance and Establishes Share Buyback Framework Motley Fool · November 12, 2026, 18:00 UTC
Flex Announces Strategic Spin-off of Cloud and Power Infrastructure Segment into Axiom Motley Fool · November 12, 2026, 18:00 UTC
Extreme Networks Raises Fiscal 2027 Revenue Guidance Amid Strong SaaS Growth and Large Enterprise Bookings Motley Fool · November 12, 2026, 18:00 UTC
Federal Reserve to Designate October 2027 Meeting as Nonvoting Strategic Session CNBC · November 12, 2026, 17:48 UTC